A clinical review finds increasing evidence for cannabinoids in ASD, Tourette syndrome, anxiety, and PTSD, with practical dosing: start 1-2.5 mg THC/day, titrate to 10-20 mg daily.
Psychiatrists considering cannabinoid prescriptions, patients with treatment-resistant mental illness, and medical cannabis program administrators.
What the researchers found
Increasing evidence supports cannabinoids for ASD, Tourette syndrome, anxiety disorders, and PTSD. THC-containing extracts may serve as substitution therapy for CUD. Practical dosing: start 1-2.5 mg THC/day, titrate by 1-2.5 mg every 3-5 days, target 10-20 mg/day. CBD requires >400 mg/day.
Why it matters
As more patients self-medicate with cannabis, clinicians need practical guidance on when cannabinoids may be appropriate and how to dose them.
The numbers in context
Starting dose: 1-2.5 mg THC/day. Titration: 1-2.5 mg every 3-5 days. Target: 10-20 mg THC/day. CBD: >400 mg/day. No approved psychiatric indications.
How the study worked
Clinical review and practical overview of cannabinoids for mental illnesses, including treatment protocols and dosing guidance.
What this study cannot tell us
Narrative review. Most evidence is preliminary. Dosing based on clinical experience as much as controlled data.
How to read the evidence
Practical clinical review with expert dosing recommendations. Evidence quality varies significantly by condition.
When this study was published
2024 publication.
The bigger picture
The gap between patient self-medication and clinical evidence is narrowing, with evidence accumulating enough to inform clinical decision-making for specific conditions.
Questions still open
- Will any cannabinoid achieve psychiatric regulatory approval soon?
- Can the endocannabinoid system's stress management role be leveraged therapeutically?
Common questions
Can cannabis treat mental illness?
What is the right dose?
Read the original research
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.
Pharmacopsychiatry, 57(3), 104-114
Citation
Müller-Vahl, Kirsten R. (2024). Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.. Pharmacopsychiatry, 57(3), 104-114. https://doi.org/10.1055/a-2256-0098
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk